Getting Funded

By Bonnie Fendrock, President and CEO of Hepregen Corporation, a Massachusetts-based company that is developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. Read more about Hepregen.

In 2008, when our team was in the early stages of starting Hepregen Corporation, TCN’s programs offered a myriad of relevant topics faced by start-up companies. We had assembled a founding team with core technology to be licensed from MIT. As CEO, I attended programs and met individuals who furthered my understanding of the implications of different financing strategies. Since we had several different business models that could be pursued, it was important that we understand the upside as well as the downside of the financing options to support each model. At every event, I gained additional insight and perspective to issues relevant to early company formation. As we headed into the Series A fund raising process, I found that we had addressed and resolved many of the questions that arise during financing as a result of my participation in TCN’s programs.

Since closing the $5M round of Series A financing from Battelle Ventures in July 2008, we have grown to 12 full time employees based in Medford, MA. We are partnering with more than a dozen pharmaceutical companies to validate Hepregen’s technology platform, HepatoPac^TM , a highly predictive liver model to assess drug safety. We are working towards commercial agreements with several major pharmaceutical companies with the goal of reaching profitability by the end of 2012.

——————-

TCN is proud to have contributed to Hepregen’s success in raising capital. Consider purchasing a TCN Season Pass to take advantage of TCN’s programs at a discounted rate.